Tysabri gets positive review for Crohn’s disease in US

Two FDA advisory panels recommended approving Tysabri for patients with moderate-to-severe Crohn’s disease who have failed on other drugs. Marketed by Biogen Idec and Elan, Tysabri is already approved for MS. An approval in this Crohn’s population may not boost the drug’s profits very much, but the advisory panels’ decision suggests concerns about the drug’s safety were tempered by its benefits. Tysabri has been linked to a rare viral infection of the brain (PML) and was temporarily withdrawn.

- see this release from Elan